^Price, GW; Burton, MJ; Collin, LJ; Duckworth, M; Gaster, L; Göthert, M; Jones, BJ; Roberts, C; Watson, JM (1997). „SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors”. Naunyn-Schmiedeberg's archives of pharmacology. 356 (3): 312—20. PMID9303567. doi:10.1007/PL00005056.
^Matsuoka, T; Hasuo, H; Akasu, T (2004). „5-Hydroxytryptamine 1B receptors mediate presynaptic inhibition of monosynaptic IPSC in the rat dorsolateral septal nucleus”. Neuroscience research. 48 (3): 229—38. PMID15154669. doi:10.1016/j.neures.2003.11.004.
^Yan, QS; Zheng, SZ; Yan, SE (2004). „Involvement of 5-HT1B receptors within the ventral tegmental area in regulation of mesolimbic dopaminergic neuronal activity via GABA mechanisms: a study with dual-probe microdialysis”. Brain Research. 1021 (1): 82—91. PMID15328035. doi:10.1016/j.brainres.2004.06.053.
^Lee, JJ; Hahm, ET; Lee, CH; Cho, YW (2008). „Serotonergic modulation of GABAergic and glutamatergic synaptic transmission in mechanically isolated rat medial preoptic area neurons”. Neuropsychopharmacology. 33 (2): 340—52. PMID17392733. doi:10.1038/sj.npp.1301396.
^Tatarczyńska, E; Kłodzińska, A; Stachowicz, K; Chojnacka-Wójcik, E (2004). „Effects of a selective 5-HT1B receptor agonist and antagonists in animal models of anxiety and depression”. Behavioural Pharmacology. 15 (8): 523—34. PMID15577451. doi:10.1097/00008877-200412000-00001.
^Chojnacka-Wójcik, E; Kłodzińska, A; Tatarczyńska, E (2005). „The anxiolytic-like effect of 5-HT1B receptor ligands in rats: a possible mechanism of action”. The Journal of pharmacy and pharmacology. 57 (2): 253—7. PMID15720791. doi:10.1211/0022357055399.